BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15657365)

  • 1. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.
    Ifergan I; Jansen G; Assaraf YG
    Mol Pharmacol; 2005 Apr; 67(4):1349-59. PubMed ID: 15657365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.
    Ifergan I; Shafran A; Jansen G; Hooijberg JH; Scheffer GL; Assaraf YG
    J Biol Chem; 2004 Jun; 279(24):25527-34. PubMed ID: 15047700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
    Lemos C; Kathmann I; Giovannetti E; Dekker H; Scheffer GL; Calhau C; Jansen G; Peters GJ
    Int J Cancer; 2008 Oct; 123(7):1712-20. PubMed ID: 18623116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
    Assaraf YG
    Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
    Rhee MS; Schneider E
    Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
    Lemos C; Kathmann I; Giovannetti E; Beliën JA; Scheffer GL; Calhau C; Jansen G; Peters GJ
    Mol Cancer Ther; 2009 Mar; 8(3):655-64. PubMed ID: 19240161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
    Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH
    Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment.
    Hooijberg JH; de Vries NA; Kaspers GJ; Pieters R; Jansen G; Peters GJ
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):1-12. PubMed ID: 16362298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
    Mohrmann K; van Eijndhoven MA; Schinkel AH; Schellens JH
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):344-50. PubMed ID: 15875186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).
    Hooijberg JH; Jansen G; Assaraf YG; Kathmann I; Pieters R; Laan AC; Veerman AJ; Kaspers GJ; Peters GJ
    Biochem Pharmacol; 2004 Apr; 67(8):1541-8. PubMed ID: 15041471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of adaptation to folate deficiency.
    Ifergan I; Assaraf YG
    Vitam Horm; 2008; 79():99-143. PubMed ID: 18804693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.